AnaptysBio, Inc. (ANAB) vs Maze Therapeutics, Inc. (MAZE)

AnaptysBio, Inc. and Maze Therapeutics, Inc. are both Biotechnology companies. AnaptysBio, Inc. and Maze Therapeutics, Inc. are of similar size ($1.6B and $1.5B). Maze Therapeutics, Inc. has the higher net margin (0.00% vs −11.5%) and the lower return on invested capital (−112.4% vs 0.00%). Across the 13 metrics below, AnaptysBio, Inc. leads on 9 and Maze Therapeutics, Inc. on 4.

Valuation

Metric ANAB MAZE Biotechnology median
P/E n/m n/m 7.88
P/S 6.30 n/m 11.47
P/B 114.79 3.39 2.52
Price to free cash flow 331.88 n/m 21.16
EV/EBITDA 37.47 n/m 0.74
EV/Sales 6.47 n/m 10.73
Earnings yield (1.67%) (9.67%) (28.84%)
Free cash flow yield 0.30% (6.95%) (23.03%)

Profitability

Metric ANAB MAZE Biotechnology median
Gross margin 100.00% — 65.16%
Operating margin 17.56% 0.00% 0.00%
Net margin (11.53%) 0.00% 0.00%
Free cash flow margin 1.90% 0.00% 0.00%
Return on equity (114.55%) (37.35%) (57.72%)
Return on assets (7.13%) (31.99%) (49.22%)
Return on invested capital 0.00% (112.36%) 0.00%

Growth

Metric ANAB MAZE Biotechnology median
Revenue growth (TTM) 107.73% — 5.64%
EPS growth (last fiscal year) 91.02% (344.00%) —
Revenue growth, 5-year CAGR 25.62% — 8.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ANAB MAZE Biotechnology median
Debt to equity 0.00 0.09 0.00
Current ratio 7.58 18.31 4.73
Net debt to EBITDA (6.84) 2.43 0.96

Dividend

Metric ANAB MAZE Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric ANAB MAZE Biotechnology median
Market cap 1.55b 1.48b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack